Clinical trial

First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients

NCT04537286

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-08-25

PhasePHASE2

Study timeline

Study start (actual)2020-08-25Date precision: day

Registry last updated2026-07-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

TNBC - Triple-Negative Breast Cancerunresolved

Interventions

nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)DRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04537286 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.